Sana Biotechnology, Inc. (SANA) stock
SANANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.85−0.03 (-1.60%)
Close on Nov 18, 2026Market cap $553.82MP/E –Yield –
Sana Biotechnology r&d expenses
Research and development expenses are spending on new products and technology.
Sana Biotechnology's R&D Expenses for the twelve months ending Jun 30, 2026 was $124.48M, down 24.7% year over year. For fiscal 2025 it was $131.98M, down 38.8% from the year before. The highest annual figure on record is $285.89M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $131.98M | -38.8% |
| FY2024 | Dec 31, 2024 | $215.67M | -17.6% |
| FY2023 | Dec 31, 2023 | $261.81M | -8.4% |
| FY2022 | Dec 31, 2022 | $285.89M | +15.0% |
| FY2021 | Dec 31, 2021 | $248.63M | +87.0% |
| FY2020 | Dec 31, 2020 | $132.94M | +33.5% |
| FY2019 | Dec 31, 2019 | $99.59M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $30.73M | +3.3% |
| Q1 FY2026 | Mar 31, 2026 | $28.72M | -22.8% |
| Q4 FY2025 | Dec 31, 2025 | $34.92M | -22.6% |
| Q3 FY2025 | Sep 30, 2025 | $30.11M | -43.4% |
| Q2 FY2025 | Jun 30, 2025 | $29.76M | -51.1% |
| Q1 FY2025 | Mar 31, 2025 | $37.19M | -34.1% |
| Q4 FY2024 | Dec 31, 2024 | $45.15M | -19.4% |
| Q3 FY2024 | Sep 30, 2024 | $53.21M | -18.9% |
| Q2 FY2024 | Jun 30, 2024 | $60.87M | -16.7% |
| Q1 FY2024 | Mar 31, 2024 | $56.45M | -16.0% |
| Q4 FY2023 | Dec 31, 2023 | $55.99M | -12.4% |
| Q3 FY2023 | Sep 30, 2023 | $65.61M | -14.5% |
| Q2 FY2023 | Jun 30, 2023 | $73.04M | +0.7% |
| Q1 FY2023 | Mar 31, 2023 | $67.17M | -7.6% |
| Q4 FY2022 | Dec 31, 2022 | $63.92M | -41.1% |
| Q3 FY2022 | Sep 30, 2022 | $76.74M | +44.1% |
| Q2 FY2022 | Jun 30, 2022 | $72.54M | +61.2% |
| Q1 FY2022 | Mar 31, 2022 | $72.69M | +73.6% |
| Q4 FY2021 | Dec 31, 2021 | $108.51M | +197.3% |
| Q3 FY2021 | Sep 30, 2021 | $53.25M | +32.9% |
| Q2 FY2021 | Jun 30, 2021 | $45.00M | +50.0% |
| Q1 FY2021 | Mar 31, 2021 | $41.88M | +53.3% |
| Q4 FY2020 | Dec 31, 2020 | $36.49M | – |
| Q3 FY2020 | Sep 30, 2020 | $40.06M | – |
| Q2 FY2020 | Jun 30, 2020 | $29.99M | – |
| Q1 FY2020 | Mar 31, 2020 | $27.32M | – |
See a number that looks wrong?